In summary, the present study suggests safety and reasonable tolerability of G-CSF application over the course of 10 days, even in the vulnerable population of elderly stroke patients with concomitant diseases like hypertension, diabetes, and WMH, known to increase morbidity and mortality [34]. The gene discussed is CSF3; the disease is stroke disorder.